Par Drugs and Chemicals Limited (IN:PAR)
:PAR
Want to see IN:PAR full AI Analyst Report?
PAR Stock Chart & Stats
₹100.93
-₹2.28(-1.11%)
At close: 4:00 PM EST
₹100.93
-₹2.28(-1.11%)
Day’s Range― - ―
52-Week Range₹78.05 - ₹122.43
Previous CloseN/A
Volume42.53K
Average Volume (3M)31.06K
Market Cap
₹1.03B
Enterprise Value₹633.62M
Total Cash (Recent Filing)₹338.56M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)7.4
Beta0.94
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.87
Shares Outstanding12,304,636
10 Day Avg. Volume60,109
30 Day Avg. Volume31,062
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)0.86
Price to Sales (P/S)0.93
P/FCF Ratio6.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero-debt Balance SheetA zero-debt position materially reduces financial risk and interest burden, giving management durable flexibility to fund R&D, capex or M&A from internal resources. For a specialty/generic drug maker this strengthens resilience to industry cycles and preserves strategic optionality over months.
Consistent Positive Free Cash FlowPositive free cash flow across periods shows the business can generate cash to fund operations and reinvest without relying on new debt. Operating cash surpassing net income in key years supports sustainable internal funding for growth, payouts, or working-capital needs over the medium term.
Solid Margins And ROEA net margin near 12.6% and mid-teens ROE historically indicate efficient operations and decent capital returns. This level of profitability supports reinvestment and signals the core business model earns value persistently, providing a durable earnings base even if growth lags.
Bears Say
Uneven Revenue GrowthIrregular revenue patterns reduce predictability for investment and capacity planning. Episodic growth suggests potential product concentration, demand variability, or execution inconsistency, making multi-quarter forecasting and sustained scale-up of sales more challenging for management.
Margin Volatility / CompressionObserved margin compression and volatility point to pressure on pricing or variable input costs, reducing the reliability of earnings. Persistent margin swings weaken the company's ability to consistently fund R&D, capex or dividends and raise execution risk over the medium term.
Uneven Cash ConversionWorking-capital swings and inconsistent conversion of profits into cash create earnings-quality concerns and can constrain near-term liquidity despite positive FCF overall. This variability makes funding timing for capex, payouts or unexpected needs less predictable over the coming months.
Par Drugs and Chemicals Limited News
PAR FAQ
What was Par Drugs and Chemicals Limited’s price range in the past 12 months?
Par Drugs and Chemicals Limited lowest stock price was ₹78.05 and its highest was ₹122.43 in the past 12 months.
What is Par Drugs and Chemicals Limited’s market cap?
Par Drugs and Chemicals Limited’s market cap is ₹1.03B.
When is Par Drugs and Chemicals Limited’s upcoming earnings report date?
Par Drugs and Chemicals Limited’s upcoming earnings report date is Jul 31, 2026 which is in 72 days.
How were Par Drugs and Chemicals Limited’s earnings last quarter?
Par Drugs and Chemicals Limited released its earnings results on May 14, 2026. The company reported ₹0.69 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.69.
Is Par Drugs and Chemicals Limited overvalued?
According to Wall Street analysts Par Drugs and Chemicals Limited’s price is currently Overvalued.
Does Par Drugs and Chemicals Limited pay dividends?
Par Drugs and Chemicals Limited pays a Notavailable dividend of ₹1.25 which represents an annual dividend yield of N/A. See more information on Par Drugs and Chemicals Limited dividends here
What is Par Drugs and Chemicals Limited’s EPS estimate?
Par Drugs and Chemicals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Par Drugs and Chemicals Limited have?
Par Drugs and Chemicals Limited has 12,304,636 shares outstanding.
What happened to Par Drugs and Chemicals Limited’s price movement after its last earnings report?
Par Drugs and Chemicals Limited reported an EPS of ₹0.69 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.398%.
Which hedge fund is a major shareholder of Par Drugs and Chemicals Limited?
Currently, no hedge funds are holding shares in IN:PAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Par Drugs and Chemicals Limited
Par Drugs and Chemicals Limited develops, produces, and sells active pharma ingredients and fine chemicals in India. It offers magnesium salts, dried aluminum hydroxide gel, sodium aluminum silicate, precipitated silica, magnesium silicate, colloidal silicon dioxide, sucralfate USP, and amorphous and blended products. The company also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.
Technical Analysis
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Brooks Laboratories Limited
―
Vivimed Labs Limited
―